Notice to Clarify Eligibility Requirements of Program Directors/Principal Investigators (PDs/PIs) in PAR-21-301 “NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed)”
Notice Number:
NOT-CA-22-141

Key Dates

Release Date:

October 26, 2022

Related Announcements

PAR-21-301 - NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed).

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to clarify the eligibility of Program Directors/Principal Investigators (PDs/PIs) in PAR-21-301 "NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed)."

The following section of the FOA is revised accordingly:

Part 2. Section III. Eligibility Information

Eligible Individuals (Program Director/Principal Investigator)

Enhancing Diversity:
Current Language:

For the purposes of this funding opportunity announcement, only individuals from categories A and B are eligible to apply for support under this program.

Revised Language:

For purposes of this funding opportunity announcement, individuals from diverse backgrounds, including the categories listed Notice of NIH’s Interest in Diversity are encouraged to apply for support under this program.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Behrous Davani, PhD
National Cancer Institute (NCI)
Telephone: 240-276-6170
Email: behrous.davani@nih.gov